Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
For those of u who got a bloodied nose in this stock(me included) you may want to look at a company with the ticker HAYD. A lot of similarities leading up to the retail offer,bookbuild etc with the defunct YGEN. Please DYOR not a recommendation!!
https://www.bookbuild.live/deals/2L7WJQ/authorised-intermediaries
You can always call them and pose the question
Just had a look @ ODDO's website (https://www.oddo-bhf.com/en) and this is a financial company managing 128 B worth of assets. Don't think this type of company is investing for the price to move from 0.48p to 0.52p!! In this climate the clue is to follow the money
Knew this company was gonna be sold, but please not @ this price!! On L2 the MMs have increased their EMS holding from an average of 30,000 shares to 150,000. A lot of share trading anticipated
Hedge- Just to reinforce ure point, i have posted a snap shot from a previous poster highlighting the directors averages
Going through all their trades pre- and post-Placing, these are the BoD's holdings, averages and total investment to date:
Bill Chang - 302,920,142 shares @ average 2.22p - c. £6,725,000 invested*
Lyn Rees - 85,371,235 @ average 0.521p - c. £445,000 invested
Adam Reynolds - 39,807,106 @ average 1.33p - c. £529,435 invested**
Stephen Little - 33,393,402 @ average 1.08p - c. £360,650 invested**
John Brown - 33,685,783 @ average 0.448p - c. £151,000 invested
Barry Hextall - 6,500,00 @ average 1.76p - c.114,500 invested
Hayden Jeffreys - 3,827,482 @ average 2.13p - c. £81,350 invested
So, today, not one director is above water with John Brown roughly breaking even (0.45), Lyn Rees needing 0.52 and the others needing at least 1p+ and Bill the highest needing 2.22p just to break even, which is nearly 6x where we are now, or a MCAP of c.£70m.
* Bill's average includes his initial 45m shares valued at c.£4m when Yourgene was taken over
** Both Adam and Stephen began with 2,301,137 and 2,272,727 respectively when Premaitha was born but I cannot find out what that 'cost' them so their averages of 1.33p and 1.08p are actually much higher in real life.
Conclusion: We can complain as much as we like, and with considerable justification, however your BoD have invested at least £8,406,935 and the largest investor would like 2.22p to break even. So, it's not all doom and gloom, follow the BoD, be patient and one should take heart that they are not investing without expecting a serious re-rating imho! GLA
Nope, check them out here.
https://www.wcgplc.co.uk
Here are the current top Institutional investors according to the financial times. Walker crips is a new large holder.
BGF Investment Management Ltd. AS OF 11 JAN 2023 399.26m 12.57%
Hargreaves Lansdown Stockbrokers Ltd.
AS OF 02 FEB 2023
270.28m 8.51%
Walker Crips Investment Management Ltd.
AS OF 02 FEB 2023
249.10m 7.84%
Jarvis Investment Management Ltd.
AS OF 02 FEB 2023
227.76m 7.17%
UBS Asset Management Switzerland AG
AS OF 02 FEB 2023
61.56m 1.94%
HSBC Global Asset Management (UK) Ltd.
AS OF 02 FEB 2023
53.66m 1.69%
Hargreaves Lansdown Asset Management Ltd.
AS OF 02 FEB 2023
40.83m 1.29%
T. Bailey Fund Services Ltd.
AS OF 11 JUL 2022
37.82m 1.19%
Cantor Fitzgerald Europe
AS OF 02 FEB 2023
32.69m 1.03%
KW Investment Management Ltd.
AS OF 02 FEB 2023
28.82m 0.91%
Dav
As far a i know, Ygen has several strategic partnerships. Some of them are named some are not
RNS of 10/2020 "...Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces it has entered into a 5-year strategic partnership with a blue chip Japanese multinational...."
RNS of 12/2021"...Successful attainment of earn-out milestones for the Coastal Genomics business acquired in H1 FY21, with $2m equity issued. Over performance due to contract wins with two US diagnostic majors of which Labcorp...."
RNS of 01/22 "...EKF Diagnostics Holdings plc (AIM: EKF), the?AIM-listed point-of-care business, has signed a strategic partnership agreement with Yourgene Health..."
RNS 0f 04/22 "....Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the Company has extended its strategic partnership with Ambry Genetics ('Ambry')....."
RNS of 08/22 "....strategic partnership with DeepVerge ..."
Out of all of these it seems Ambry is the only one gaining traction. I cant find any mention of the other US company(Labcorp) on the new website, so it seems logical this is where the focus lies in my opinion
Dav
My point is why is it there in the first place? Yourgene could not have put any reference to Ambry on their website without their permission, or else they could be sued. Why would ambry advertise their products on a small company's website, when they have their own? You can connect the dots and see what is happening!!
Brighty
My thoughts exactly and if one browses through yourgene health's website u can find the collaboration with Ambry Genetics with their Oncology Cancer Next product. Too much of a coincidence for me !!
I can understand and share peoples frustration here, but did anyone notice the company that seems to be part of your gene health? Click on Our services, go down to Oncology and you will see Cancer next and RNAinsight both powered by Ambry!!
You may find this interesting in the current climate
https://www.griproom.com/fun/10-signs-your-company-is-about-to-be-acquired
Well it could be that a hostile bid my trigger a counter bid which would be out of the control of the original bidder. This way , the company would have a stake (equity ) and lessen any costs in any counter bid. But this is just speculation.
Sorcerer Ok i can only guess its to do with money, profit or call it what you like
So for example, GL trader quoted lyns holding before the placing as follows:
1,000,000 @ 7p (2022)
294,000 @ 17p (2020)
243,902 @ 10.25p (2019)
500,000 @ 10p (2018)
Thus for investment of 2,037,902 shares, his initial investment amounts to £194,979.96 (excluding any options etc)
Thus @ 6pence his holding will amount to £122,274.12 a loss of £72,705.84
After the placing he will have 85,371,235 and as i have mentioned before his average price will be reduced to 0.52 pence
A takeover price of 6 pence will bring him 85,371,235 x £0.06 = £5,122,274.10 !!!
You can clearly see the difference. So its all down to cash . I could be wrong, but i doubt it
You are welcome Sir and like others have said, nice to see you back
Alot of retail participants go through brokers such as Halifax, barclays, Hargreaves, ....etc and the intermediaries mentioned do not include them. If you are not already a stock holder with the intermediaries, then no show as i understand it. I think lionheart gave a good explanation
...So i am speculating that a buyer could well swoop into the second tranche and within a stroke own approximately 50% of the company.
Note in the above table for a take over price of 6 pence, the market capitalisation is about 191m ( assuming that the retail offer is completely subscribed- doubt it somewhat).If an entity owns the second tranche, they will only need to stump up 102M
##################Retail Offer#################
As Lionheart has mentioned, most retail investors will not be able to participate in this offer. But look what happens to the calculation on no retail shares
Placing Shares Price pence Price Pounds Raised Amount
First placing 66,080,000 0.3 £0.0030 £198,240.00
Second placing 1,568,920,001 0.3 £0.0030 £4,706,760.00
Director Subscription 499999999 0.3 £0.0030 £1,500,000.00
Retail ########## 0.3 £0.0030 ############
Total Placing Shares 2,135,000,000 £6,405,000.00
Current Shares pre-placing 727100243
Grand total Shares 2,862,100,243
Market Cap @6p £171,726,014.58 6 0.06
Company Liability £82,297,574.52
So the liability drops to about 20% if no retail investors participate. Hmmm i wonder......
This is just speculation, but the figures seem to bear out an interesting scenario
On page 15 , the following was documented
"The Company is pleased to confirm that the Placing and Subscriptions have conditionally raised gross
proceeds of £6.4 million, and it intends to raise up to a further £1.0 million through the Retail Offer."
So it seems the buyer/buyers have already been lined up. Interesting to know who it is right?? :)
Also , by Yourgenes admission the following statement was documented
"Yourgene are fully aware of the legal dispute occurring between the small biotech Ravgen and the largest reference lab in the US . Yourgene can confirm that they are not connected to the legal disputes taking place and it has no negative impact on the IONA test.”
I believe this case was lost by a big US diagnosis organisation, so why spend money on future litigations and royalties, when this is ripe for the plucking??
If it walks like a duck, quacks like a duck then who knows ......
Also another point , the Director subscription comprises of 499,999,999 shares of which 383,333,332 are for the actual directors of the company and 116,666,667 (see page 20) are for IMPORTANT existing ordinary shareholders!! Who are they please?
Another point, on page 17 I lifted this quote
"advancing ongoing discussions regarding a potential strategic investment from a leading organisation operating in the same sector as Yourgene (the “Strategic Investment”)."
Is it still advancing or a done deal??? Alot to ponder folks.
I have been going through some figures courtesy of the following link
https://www.yourgene-health.com/images/PDFs/gatepost/YGEN-Circular-23-Dec-22.pdf. Similar to the RNS, but easier to decipher
The table below shows the Placing shares available and the associated amounts
Placing Shares Price pence Price Pounds Raised Amount
First placing 66,080,000 0.3 £0.0030 £198,240.00
Second placing 1,568,920,001 0.3 £0.0030 £4,706,760.00
Director Subscription 499999999 0.3 £0.0030 £1,500,000.00
Retail 333333333 0.3 £0.0030 £1,000,000.00
Total Placing Shares 2,468,333,333 £7,405,000.00
Current Shares pre-placing 727100243
Grand total Shares 3,195,433,576
Market Cap @ 6pence £191,726,014.56 6 0.06
Company Takeover Liability @ 6 pence £102,297,574.50
The current placing shown as ' First Placing ' has been initiated. What has drawn my first attention is the second placing to happen next week. Here the interesting feature is who is NOT PARTICIPATING!!
1. No directors, they have their own placing
2 No retail investors
3. Life sciences and Steve Myers seem not be interested in this. If one proceeds to page 18, i have lifted the following text. (In the glossary LTL is Life technologies limited).
"LTL, a Shareholder, is entitled to participate on a basis which is pro rata to its existing shareholding in the Company in any new issue of Ordinary Shares by the Company (which would include each of the First Placing, the Second Placing, the Subscriptions and the Retail Offer) on the same price and on the same terms as those offered to prospective investors (each an “LTL Offer”) and must be notified of such an LTL Offer by the Company in advance. The Company has issued an LTL Offer in respect of the Capital Raising to LTL, but, at the date of this document, it is not known whether LTL intends to exercise its pre-emption rights in respect of any or all of that LTL Offer. Taking into account the number of Ordinary Shares proposed to be issued and allotted in connection with the Capital Raising, a sufficient number of Ordinary Shares has been allocated provisionally to LTL, such that if LTL chooses to accept the LTL Offer related to the Capital Raising, the Directors are or will be authorised to issue and allot such number of New Ordinary Shares to LTL as are comprised in that LTL Offer under the share allotment authorities which were conferred at the 2022 AGM and/or the share allotment authorities which will be conferred by the passing of Resolution 1 and Resolution 2 at the General Meeting.If LTL does so elect to participate in the Capital Raising, the allocation of Capital Raising Shares to other investors will be scaled back accordingly, on such basis as the Company and the Boo krunner and Broker" ......continued
Read the latest RNS's, good place to start. Also make sure u have a few quid in the bank if u are a current shareholder. U will need it
GLT, looks like lyns average is 0.52 pence. Makes sense with the amount of shares he has purchased @ £0.0030